Aberrant epigenetic gene regulation by deacetylation of histone proteins has been involved
in tumorigenesis. Histone deacetilase (HDAC) inhibitors are promising anticancer agents …

Introduction: Romidepsin is a potent and selective inhibitor of histone deacetylases (HDCAi).
It is also the only bicyclic inhibitor to undergo clinical assessment and is considered a …

Introduction: Romidepsin is a novel histone deacetylase (HDAC) inhibitor, with a recent
approval for treatment of cutaneous T-cell lymphoma (CTCL). HDAC inhibitors represent a …

8027 Background: The histone deacetylase inhibitors (HDIs) are a class of differentiating
agents undergoing clinical testing. Like other HDIs, romidepsin (FK228) modulates …

Romidepsin is a histone deacetylase inhibitor (HDI), approved by the US FDA for the
treatment of cutaneous T-cell lymphoma (CTCL). Although various mechanisms have been …

Histone deacetylase (HDAC) inhibitors are epigenetic-modifying agents that have shown
promise as anticancer therapies. Several HDAC inhibitors have been approved by the US …

Purpose The pharmacology, pharmacokinetic and pharmacodynamic properties, and
clinical data on a novel therapy for the treatment of cutaneous or peripheral T-cell lymphoma …

Romidepsin is an epigenetic agent approved for the treatment of patients with cutaneous or
peripheral T‐cell lymphoma (CTCL and PTCL). Here we report data in all patients treated on …

Purpose The primary objective of this study was to confirm the efficacy of romidepsin in
patients with treatment refractory cutaneous T-cell lymphoma (CTCL). Patients and Methods …

Romidepsin is a histone deacetylase inhibitor with high inhibitory activity for class I histone
deacetylases. Intravenous romidepsin is indicated in the US for the treatment of adult …